Recombinant Tetranychus urticae Uncharacterized protein-VLPs

Shipped with Ice Packs
In Stock

Description

Definition and Context

Recombinant Tetranychus urticae Uncharacterized Protein-VLPs (virus-like particles) refer to non-infectious nanostructures engineered to mimic the structural proteins of viruses but derived from an uncharacterized protein of Tetranychus urticae (the two-spotted spider mite). VLPs are typically produced by heterologous expression of viral structural genes in recombinant systems (e.g., bacterial, yeast, insect, or plant cells) and self-assemble into particles devoid of genetic material . In this case, the VLP scaffold incorporates an undefined protein from T. urticae, likely for antigen presentation, diagnostic applications, or targeted delivery systems.

Applications

  • Vaccine Development: VLPs displaying mite-derived antigens could induce immune responses against T. urticae infestations, analogous to allergen-coupled plant virus VLPs (e.g., TuMV-Pru p 3 for food allergy treatment) .

  • Diagnostics: VLPs serve as antigens in serological assays to detect mite-specific antibodies .

  • Nanocarriers: Functionalized VLPs may deliver acaricides or RNAi molecules to mite populations .

Challenges

  • Protein Characterization: The term “uncharacterized” implies unresolved structural/functional details, complicating VLP design and stability .

  • Immunogenicity: Without adjuvants, mite-derived VLPs may exhibit weak immunostimulation compared to viral VLPs .

  • Scalability: Optimization of expression systems (e.g., yield in plants vs. insect cells) is critical for commercial viability .

Comparative Analysis of VLP Platforms

ParameterInsect CellsMammalian CellsPlants
YieldModerateLowHigh
Post-Translational ModificationsYesHuman-likePlant-specific
CostHighVery HighLow
ScalabilityModerateLimitedHigh
Data synthesized from

Research Gaps and Future Directions

  1. Structural Resolution: Cryo-EM or X-ray crystallography is needed to resolve the uncharacterized protein’s topology and assembly mechanisms .

  2. Functional Studies: In vitro/in vivo assays (e.g., PBMC proliferation, murine allergy models) could validate immunomodulatory potential .

  3. Safety Profiling: Toxicity studies (e.g., BUN, galectin-3 levels) must ensure biocompatibility .

Product Specs

Buffer
Lyophilized from PBS, 6% Trehalose, pH 7.4
Form
Lyophilized powder
Note: We will ship the product in lyophilized form with standard blue ice packs by default. If you require liquid form, it must be shipped with dry ice. Please communicate your preference in advance, as additional fees will apply for dry ice and dry ice packaging.
Lead Time
Delivery time can vary depending on the purchase method and location. Please contact your local distributors for specific delivery timeframes.
Note: Delivery time may differ from different purchasing way or location, please kindly consult your local distributors for specific delivery time.
Notes
Repeated freezing and thawing is not recommended. Store the protein at -20°C/-80°C upon receipt and avoid repeated freeze-thaw cycles. This will help maintain the protein's activity.
Shelf Life
Shelf life depends on several factors, including storage conditions, buffer ingredients, storage temperature, and the protein's inherent stability.
Generally, liquid form has a shelf life of 6 months at -20°C/-80°C. Lyophilized form has a shelf life of 12 months at -20°C/-80°C.
Storage Condition
Store at -20°C/-80°C upon receipt. Aliquoting is recommended for multiple uses. Avoid repeated freeze-thaw cycles.
Tag Info
C-terminal 10xHis-tagged
If you require a specific tag type, please inform us and we will investigate the feasibility of developing it.
Synonyms
/
Datasheet & Coa
Please contact us to get it.
Expression Region
1-376aa
Research Area
Others
Source
Mammalian cell
Species
Tetranychus urticae (Two-spotted spider mite)
Target Names
N/A
Target Protein Sequence
MRDAFDDQTLKVTVEMTFPTALNEPDQVILDGYIVPSKYLLRQITKILLLLTIAYSSAFRIAYMYIYLLRNCKLTTKLMIIDCAHATIVAINVLLTVLMLLFAFDWNHFRKFISHIKSLSLETDRLTVRTIKQNRRITQALLIVTFIIYMIIFYTQQKAISIDTVNPFVFNLLCFHEMLIRFVFLFFLNMICNICFWLKAAFNHINSQISDLHDTSDQSFGHLFCKIRDLRQKYSYAVRSTQSAEKLFRWFITLYYIEYFTYNIVNIVMSLGPKMNIDSIWLLFISIATLYFIILTYYLVSVNNLSREGLEDLYELSFKLNTAQSCHENDIFIARMALSDVGFTFANLFTINNNFITSVFTLSFTIIITLASFIYQ
Note: The complete sequence including tag sequence, target protein sequence and linker sequence could be provided upon request.
Uniprot No.

Q&A

What are Tetranychus urticae Uncharacterized protein-VLPs and how are they characterized?

T. urticae uncharacterized protein-VLPs refer to virus-like particles composed of structural proteins from the two-spotted spider mite that have not been fully characterized. These particles resemble viruses morphologically but lack complete viral genomes. Characterization typically employs multiple complementary techniques:

Transmission electron microscopy (TEM) with negative staining allows visualization of particle morphology, revealing spherical structures typically 50-65 nm in diameter, similar to those observed in other VLP systems . Immunoelectron microscopy (IEM) can confirm the presence of specific proteins on VLP surfaces through gold-particle labeling. Western blot analysis using monoclonal antibodies confirms protein identity and expected molecular weight, while dot blot analysis of gradient fractions helps determine which fractions contain the highest VLP concentrations . Ultrastructural cytochemical characterization can identify VLP production sites within cells, showing particles in the cytoplasm, within vesicles, and budding from cell membranes .

How does the virome of T. urticae relate to potential VLP formation?

The virome of T. urticae is remarkably diverse and may contribute to endogenous VLP formation. Recent RNA deep sequencing analysis has revealed:

  • 20 distinct viral sequences associated with T. urticae, including 11 novel viruses

  • Classification of these viruses into families including Nodaviridae, Kitaviridae, Phenuiviridae, Rhabdoviridae, Birnaviridae, and Qinviridae

  • Presence of endogenous viral elements (EVEs) integrated into the T. urticae genome

These viral elements may contribute to the formation of VLPs through expression of structural proteins. Of particular interest are the endogenous viral elements (EVEs) integrated into the T. urticae genome, with sequences of 1032 nt and 1239 nt showing similarities to nucleocapsid and nucleoprotein from Rhabdoviridae family members . These integrated viral elements could potentially lead to the production of uncharacterized VLPs when expressed.

What biological roles might T. urticae VLPs play?

VLPs in arthropods may serve multiple biological functions similar to those observed in other systems:

  • Potential involvement in horizontal gene transfer

  • Possible role in host defense mechanisms

  • Mediation of virus-host interactions and viral transmission

  • Contribution to proteostasis and protein aggregate formation

What expression systems are most effective for producing recombinant T. urticae protein-VLPs?

Insect cell-based expression systems, particularly those using Sf9 cells infected with recombinant baculovirus, represent the most promising approach for producing T. urticae protein-VLPs. This methodology offers several advantages:

  • Post-translational modifications: Insect cells provide eukaryotic post-translational modifications that are more similar to those in arthropods than bacterial systems.

  • High-yield production: Baculovirus expression promotes high-level protein production, as demonstrated with Zika virus VLPs where expression was visible after 24 hours post-infection .

  • Self-assembly capability: Structural proteins expressed in Sf9 cells can self-assemble into VLPs within the cell cytoplasm and vesicles .

The experimental approach should include:

  • Construction of transfer vectors containing T. urticae structural protein genes

  • Generation of recombinant baculovirus

  • Infection of Sf9 cells with optimal MOI (typically MOI of 2 is effective)

  • Harvesting at 72 hours post-infection for optimal VLP production

Expression confirmation can be performed using immunofluorescence to detect proteins in cell membranes and Western blot analysis to confirm protein size (~55 kDa for envelope proteins in similar VLP systems) .

What purification strategies yield the highest purity of recombinant T. urticae VLPs?

Purification of T. urticae VLPs requires a multi-step approach to separate VLPs from cellular debris and baculovirus particles:

Table 1: Comparison of VLP Purification Methods

MethodAdvantagesDisadvantagesTypical RecoveryVLP Size Range
Sucrose gradientHigh recovery, preserves VLP integrityIncomplete baculovirus removal60-80%50-65 nm
Iodixanol gradientBetter separation, less osmotic damageMore expensive, technically demanding40-60%50-65 nm
Column chromatographyScalable, higher purityPotential protein denaturation30-50%Not specified

For optimal results, a combined approach is recommended:

  • Initial clarification by low-speed centrifugation (1,000×g for 10 min)

  • Pelleting of VLPs by ultracentrifugation (100,000×g for 2 hours)

  • Purification through either sucrose (20-60%) or iodixanol gradients

  • Fraction collection and analysis by dot blot with specific antibodies

  • Further characterization of enriched fractions by Western blot and TEM

Note that complete elimination of baculovirus particles remains challenging. For applications requiring higher purity, additional steps such as column chromatography or affinity purification may be necessary, or baculovirus inactivation through gamma radiation, beta-propiolactone, or formaldehyde treatment .

How can researchers optimize transmission electron microscopy for visualizing T. urticae VLPs?

Optimization of TEM for T. urticae VLP visualization requires careful sample preparation and multiple visualization techniques:

Negative staining protocol:

  • Apply 5-10 μl of purified VLP sample to carbon-coated copper grids

  • Allow adsorption for 1-2 minutes

  • Remove excess liquid with filter paper

  • Apply 2% uranyl acetate or phosphotungstic acid for 30-60 seconds

  • Remove excess stain and air dry

  • Image at 80-120 kV with appropriate magnification (50,000-150,000×)

This approach reveals spherical VLP structures ranging from 50-65 nm in diameter .

Immunoelectron microscopy (IEM):

  • Apply purified VLPs to grids as above

  • Block with 1% BSA in PBS for 30 minutes

  • Incubate with primary antibody against T. urticae structural proteins

  • Wash and incubate with gold-conjugated secondary antibody

  • Counterstain with uranyl acetate

  • Image to visualize gold particles on VLP surfaces

Ultrastructural cytochemical analysis for in situ visualization:

  • Fix infected cells with 2.5% glutaraldehyde, 2% paraformaldehyde in 0.1M cacodylate buffer

  • Post-fix with 1% osmium tetroxide

  • Dehydrate in graded ethanol series

  • Embed in resin

  • Section using ultramicrotome (70-90 nm sections)

  • Stain with uranyl acetate and lead citrate

  • Observe for VLPs in cytoplasm (30-40 nm diameter) and budding from cell membrane (50-60 nm diameter)

How can researchers distinguish between T. urticae endogenous viral elements and true virus-derived VLPs?

Distinguishing between endogenous viral elements (EVEs) and exogenous viral sequences requires a comprehensive analytical approach:

  • Genomic integration analysis: Confirm integration of viral sequences into the T. urticae genome through PCR amplification spanning virus-host junctions.

  • Transcriptomic analysis: Compare expression patterns of suspected EVEs across different T. urticae developmental stages and conditions.

  • Bioinformatic screening: Implement de novo virus discovery bioinformatics pipelines to identify and classify viral sequences, as demonstrated in recent T. urticae virome studies .

  • Conserved domain analysis: Examine for characteristic domains like Rhabdo_ncapsid that could mislead identification of exogenous viral sequences .

  • Control sequences: Use identified EVEs (such as the 1032 nt and 1239 nt sequences in T. urticae with similarity to Rhabdoviridae) as negative controls when searching for exogenous viral sequences .

The integration of these approaches enables reliable differentiation between true virus-derived VLPs and those originating from endogenous viral elements, preventing misinterpretation of experimental results.

What are the challenges in expressing multiple T. urticae structural proteins for complex VLP assembly?

Assembly of complex VLPs from multiple T. urticae structural proteins presents several challenges:

  • Stoichiometric expression: Maintaining appropriate ratios of multiple structural proteins is critical for proper VLP assembly. Strategies include:

    • Using multiple promoters with different strengths

    • Employing IRES (Internal Ribosome Entry Site) elements

    • Creating polycistronic constructs with self-cleaving peptides

  • Sequential assembly requirements: Some VLPs require sequential incorporation of proteins. In systems like Zika virus VLPs, proper assembly depends on coordinated expression of capsid (C), premembrane (prM), and envelope (E) proteins .

  • Post-translational modifications: T. urticae proteins may require specific modifications for proper folding and assembly. Note that proteins produced in insect cells may have different glycosylation patterns than those in mammalian cells, as observed with the 55 kDa E protein in the Zika VLP system .

  • Protein toxicity: Some structural proteins may be toxic to host cells when overexpressed, necessitating inducible systems or optimization of expression timing.

  • Confirmation of complex assembly: Verification of proper multi-protein VLP assembly requires sophisticated analytical techniques including:

    • Size-exclusion chromatography

    • Dynamic light scattering

    • Multi-angle light scattering

    • Cryo-electron microscopy for structural analysis

How might T. urticae VLPs influence protein aggregation and cellular stress responses?

Recent research has revealed intriguing connections between VLPs, protein aggregation, and cellular stress that may be relevant to T. urticae biology:

By extension, T. urticae VLPs might similarly influence protein quality control mechanisms within the mite, with potential impacts on:

  • Stress tolerance: VLPs could affect T. urticae's ability to withstand environmental stressors (temperature, pesticides, etc.)

  • Aging processes: As VLPs have been linked to aging in yeast and mammals, they might influence T. urticae lifespan and reproductive senescence .

  • Protein aggregate sequestration: VLPs may participate in mechanisms that sequester potentially toxic protein aggregates, similar to the mitochondrial sequestration observed in yeast .

  • Disease susceptibility: The presence of VLPs might influence susceptibility to pathogenic infection or transmission capability.

Experimental approaches to investigate these hypotheses could include RNAi knockdown of T. urticae retroelement expression followed by proteostasis assessments and stress challenge experiments.

What bioinformatic approaches are recommended for identifying novel VLPs in T. urticae genomic and transcriptomic data?

Comprehensive identification of novel VLPs in T. urticae data requires an integrated bioinformatic workflow:

  • Initial sequence preprocessing:

    • Quality filtering and adapter trimming of sequencing reads

    • Removal of host sequences by alignment to T. urticae reference genome

    • De novo assembly of remaining reads using multiple assemblers (Trinity, SPAdes, MEGAHIT)

  • Viral sequence detection:

    • BLAST searches against viral databases (NCBI Viral RefSeq, vFam)

    • Domain-specific searches using profile HMMs for viral hallmark proteins

    • Implementation of specialized viral detection tools like VirSorter, VirFinder, or custom de novo virus discovery pipelines

  • ORF prediction and annotation:

    • Prediction of open reading frames using tools like ORFfinder or Prodigal

    • Functional annotation focusing on viral domains (RdRp, capsid proteins)

    • Analysis of conserved domains to identify hallmarks of specific viral families

  • Phylogenetic classification:

    • Multiple sequence alignment of identified viral sequences with reference viruses

    • Phylogenetic tree construction using maximum likelihood methods

    • Classification of viral sequences into established or novel taxonomic groups

This approach has successfully identified diverse viral sequences in T. urticae, including members of Nodaviridae, Kitaviridae, and various unclassified viruses within Picornavirales, demonstrating its effectiveness for novel VLP discovery .

How can researchers quantitatively assess VLP production efficiency in different expression systems?

Quantitative assessment of VLP production requires a multi-parameter analytical approach:

Table 2: Quantitative Methods for VLP Assessment

MethodMeasurement ParameterTypical RangeAdvantagesLimitations
Dot blot analysisSignal intensity of structural proteinsSemi-quantitativeSimple, high throughputNot fully quantitative
Western blotProtein band intensity0.1-100 ng/μLConfirms correct sizeLimited dynamic range
TEM particle countingParticles per field or grid10⁹-10¹² particles/mLDirect visualizationLabor intensive, sampling bias
Dynamic light scatteringParticle size distribution20-200 nmRapid, non-destructiveCannot distinguish VLPs from other particles
ELISAProtein concentration0.1-1000 ng/mLHigh sensitivity, quantitativeRequires specific antibodies
Nanoparticle trackingParticle concentration and size10⁷-10¹² particles/mLSize and concentration dataLimited specificity

For comprehensive assessment of production efficiency:

  • Collect samples at multiple time points post-infection (24, 48, 72, 96 hours)

  • Perform dot blot analysis of fractions from purification gradients to identify peak VLP-containing fractions

  • Confirm protein identity and size by Western blot using specific antibodies

  • Quantify VLP concentration using calibrated nanoparticle tracking analysis

  • Assess purity and morphology by negative staining TEM

  • Calculate yield (mg VLP per liter of culture) and purity (% VLP protein relative to total protein)

When comparing expression systems, key metrics include volumetric productivity (mg/L), time to harvest, and the ratio of correctly assembled VLPs to total expressed protein.

What are the key considerations when interpreting potential agricultural impacts of T. urticae VLPs?

When assessing the agricultural significance of T. urticae VLPs, researchers should consider:

  • Viral transmission potential: T. urticae has been found to harbor plant-infecting viruses like Bean common mosaic virus (BCMV) and Phaseolus vulgaris alphaendornavirus 1, both important bean pathogens . Researchers should:

    • Perform controlled transmission studies with VLP-producing mites

    • Monitor viral load in plants before and after mite infestation

    • Distinguish between mechanical transmission and biologically-mediated transmission

  • Impact on mite fitness and behavior:

    • Assess whether VLP production affects mite fecundity, longevity, or feeding behavior

    • Determine if VLPs alter mite response to environmental stressors or pesticides

    • Evaluate potential changes in host plant preference or damage patterns

  • Host plant immune responses:

    • Investigate if T. urticae VLPs trigger plant immune responses

    • Determine whether VLPs facilitate or suppress plant defenses

    • Assess if VLP presence alters the nutritional quality of host plants

  • Vector control implications:

    • Evaluate if targeting T. urticae VLP production could be a viable pest management strategy

    • Assess whether VLPs increase susceptibility to biological control agents

    • Investigate potential for developing VLP-based biocontrol approaches

The discovery that T. urticae can potentially transmit important plant pathogens emphasizes the need for continuous viral surveillance to prepare for future emerging threats in agricultural systems .

Quick Inquiry

Personal Email Detected
Please use an institutional or corporate email address for inquiries. Personal email accounts ( such as Gmail, Yahoo, and Outlook) are not accepted. *
© Copyright 2025 TheBiotek. All Rights Reserved.